|  |  |  |
| --- | --- | --- |
| **PROFILE** | | |
| **1** | **NAME** | Dr June Choon Wai Yee |
| **2** | **ACADEMIC POSITION** | LECTURER |
| **3** | **STATUS OF APPOINTMENT** | PERMANENT |
| **4** | **CITIZENSHIP** | MALAYSIAN |
| **5** | **EDUCATION** | * PhD – Universiti Sains Malaysia - 2012 * Bachelor of Pharmacy (Hons) – Universiti Sains Malaysia 2006 |
| **6** | **WORKING EXPERIENCE** | * Scientific Advisor, Pharmaceutical Association of Malaysia (PhAMA). January 2023 – December 2023 * Principal Science Officer, hEOR (health Economics and Outcomes Research), Galen Centre for   Health and Social Policy. Dec 2021 – Dec 2022   * Lecturer, School of Pharmacy, Monash University Malaysia. Dec 2014 – 2021 * Senior Lecturer and Student Affairs Coordinator, School of Pharmacy, Taylor’s University, Lakeside   Campus. Jan 2013 – Nov 2014   * Senior Researcher, School of Pharmacy and Pharmaceutical Sciences, Universiti Sains Malaysia.   2008 - 2012   * Pharmacist, National Infectious Disease and Trauma Centre, Sungai Buloh Hospital. 2006 – 2007 |
| **7** | **CURRENT ACADEMIC RESPONSIBILITIES** | * Resource Person PHC672 Latihan Industri * PHD211: Semi Solid Dosage Form: Program Diploma Farmasi (PH110): Pemeriksa Kertas Peperiksaan Akhir * PHC463 Fundamentals of Pharmaceutics * PHC663 Cosmetic Science * PHP714 Pharmacoeconomics * PHC560 Nutraceuticals * UiTM Research Ethics Committee |
| **8** | **RESEARCH INTERESTS/ PROJECTS** | * Financing of innovative health technologies   + Economic evaluation of health technologies and public health policies.   + Generation and utilization of real-world evidence in economic studies. |
| **9** | **PUBLICATIONS** | **Journal articles (Indexed SCOPUS/WoS):**   1. **Budget Impact Analysis of Ferric Derisomaltose for the Treatment of Iron-Deficiency in Malaysia. 2023. Malaysian Journal of Medicine and Health Sciences.** **Chong, H.Y.; Choon, J.W.Y.; Ang, W.C.; Lee, K.K.C.** <https://doi.org/10.47836/mjmhs.19.4.17>   **2. Stakeholders’ Views on Patient Access Schemes in Malaysia. 2022. Value in Health Regional Issues.** **Thanimalai, S.; Choon, W.Y.; Lee, K.K.-C.** <https://doi.org/10.1016/j.vhri.2022.02.003>  **3. Stakeholder views of managed entry agreements: A literature review of national studies.** **Health Policy OPEN 2021.** **Thanimalai, S.; Choon, W.Y.; Lee, K.K.-C.** <https://doi.org/10.1016/j.hpopen.2021.100032>  **4. Is Dual Policy an Overarching Strategy for Medicine Price Controls in Malaysia?** **Asia Pacific Journal of Public Health 2020-05 |Wai Yee Choon; Kenneth Lee** <https://doi.org/10.1177/1010539520920526>  **5. Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong.** **Journal of Medical Economics 2019-03-04. June W. Y. Choon; David B. C. Wu; H. Y. Chong; William T. L. Lo; Catherine S. Y. Chong; W. S. Chung; Eileena M. C. Chui; Brian Tomlinson; Vivian W. Y. Lee; S. C. Lee et al.** <https://doi.org/10.1080/13696998.2018.1560749>  **6. Efficacy of oral mixed tocotrienols in diabetic peripheral neuropathy: A randomized clinical trial. JAMA Neurology 2018. Hor, C.P.; Fung, W.Y.; Ang, H.A.; Lim, S.C.; Kam, L.; Sim, S.-W.; Lim, L.H.; Choon, W.Y.; Wong, J.W.; Ch'ng, A.S.H. et al.** <https://doi.org/10.1001/jamaneurol.2017.4609>  **7. Interpretation of laboratory data and general physical examination by pharmacists.** **Clinical Pharmacy Education, Practice and Research: Clinical Pharmacy, Drug Information, Pharmacovigilance, Pharmacoeconomics and Clinical Research 2018.** **Zachariah, S.; Kumar, K.; Lee, S.W.H.; Choon, W.Y.; Naeem, S.; Leong, C.** **https://doi.org/10.1016/b978-0-12-814276-9.00007-6**  **8. A Preliminary Analysis Of Health Care Resource Utilization Of Paliperidone Palmitate In The Treatment Of Schizophrenia In The Public Health Care Sector Of Hong Kong.** **Value in Health 2016-05.** **WY Choon.** <https://doi.org/10.1016/j.jval.2016.03.1370>  **9. Use of generic medicines: Perspectives of consumers living in urban and suburban areas of Klang Valley in Malaysia.** Journal of Medical Marketing 2013. **Ali, S.M.; Manan, M.M.; Hassali, M.A.; Kassab, Y.W.; Yee, C.W.; Masri, M.B.** <https://doi.org/10.1177/1745790413516971>  **10. Harm reduction program and methadone poisoning: Implications for pediatric public health in Malaysia.** **Journal of Pharmacy Practice 2000.** **Babar, Z.-U.-D.; Nur Rashidah Mohd Zaini; Choon Wai Yee.** <https://doi.org/10.1177/0897190006295801>  **Conference Proceeding**   1. Health care resource utilization analysis of Paliperidone Palmitate in the treatment of schizophrenia in the public healthcare sector of Hong Kong. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) at Washington 2016, Vienna 2016, and ISPOR Asia-Pacific Tokyo 2018. Supported by Johnson & Johnson (Hong Kong) 2. Cost-effectiveness of Edoxaban in Patients with non- valvular atrial fibrillation and venous thromboembolism in Hong Kong. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, Glasglow 2017. Supported by Daiichi-Sankyo (Hong Kong) 3. An initial estimation of potential savings for schizophrenic patients receiving paliperidone palmitate 3-monthly injection in the public sector of Hong Kong. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, Glasglow 2017. Supported by Johnson & Johnson (Hong Kong) 4. Efficiency Drivers and Barriers Research in 3 ASEAN countries - Singapore, Malaysia and Indonesia. nternational Society for Pharmacoeconomics and Outcomes Research (ISPOR), New Orleans USA 2019. Supported by Pfizer Inc (Global). 5. Cost comparison of Diamicron MR and Generic Gliclazide in Preventing Renal Failure in Type 2 Diabetes Mellitus in the Public and Private Sector of Malaysia. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), European Congress, 2019 Copenhagen, Denmark. Supported by Servier (Malaysia) |
| **10** | **RESEARCH GRANTS** | **Principal Investigator:**   1. Impact of E-labelling Implementation on Pharmaceuticals on the Public, Healthcare Professionals, and Industries.   Collaboration with National Pharmaceutical Regulatory Agency (NPRA), Program Perkhidmatan Farmasi, Ministry of Health Malaysia, Pharmaceutical Association Of Malaysia (PhAMA), The Malaysian Organisation of Pharmaceutical Industries (MOPI) (2024)  Amount: RM21,000  Duration: 2024-2026  **Co-Investigator:**   1. Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus (VENUS). LRGS. The Performance Management and Delivery Unit (PEMANDU) & the Malaysian Palm Oil Board. RM3,000,000 (2011-2018). 2. Health care resource utilization analysis of Paliperidone Palmitate in the treatment of schizophrenia in the public healthcare sector of Hong Kong. Janssen, a division of Johnson & Johnson (HK) Ltd. HKD 395,000. (2014) 3. The analysis of Health Economics data for Dapagliflozin in Hong Kong. AstraZeneca Hong Kong Ltd . RM260,000 (2014) 4. Dapagliflozin budget impact analysis model and final budget impact analysis report. AstraZeneca. RM46,948 (Malaysia) (2016) 5. Budget impact of Secukinumab in psoriasis, psoriatic arthritis and ankylosing spondylitis in the public sector of Malaysia. Novartis. RM120,000. (2016). 6. Cost-effectiveness of Edoxaban in Patients with non- valvular atrial fibrillation and venous thromboembolism in Hong Kong. Daiichi-Sankyo (Hong Kong). HKD240,000. (2016) 7. An initial estimation of potential savings for schizophrenic patients receiving paliperidone palmitate 3-monthly injection in the public sector of Hong Kong. Johnson & Johnson (Hong Kong) HKD80,000. (2017) 8. Efficiency Drivers and Barriers Research in 3 ASEAN countries - Singapore, Malaysia and Indonesia Pfizer Inc, Global. USD40,000. (2018) 9. Cost comparison of Diamicron MR and Generic Gliclazide in Preventing Renal Failure in Type 2 Diabetes Mellitus in the Public and Private Sector of Malaysia. Servier (Malaysia) RM80,000. (2018) 10. Cost-effectiveness and Budget Impact Analysis on Non- Valvular Atrial Fibrillation Screening. Pfizer (Malaysia) RM70,000 (2020) 11. Monash-Novartis HEOR Workshop for the Ministry of Novartis (Malaysia)RM70,000 (2020) 12. Budget Impact Analysis of Adcetris. Takeda (Malaysia) RM55,000 (2021). |
| **11** | **AWARDS** | N/A |
| **12** | **INVOLVEMENT IN**  **PROFESSIONAL**  **ORGANISATIONS** | Member, International Society of Pharmacoeconomics and Outcomes Research (ISPOR) (2014 – current) |
| **13** | **PARTICIPATION IN**  **CONTINUING**  **EDUCATION** | 1. ***Member,*** Jawatankuasa Penyelidikan Kajian   Klinikal Kebangsaan (JPKKK)(2023)   1. ***Member,*** Jawatankuasa Pemandu Dasar Ubat   Nasional Penggal Ke-empat (DUNas  (2022-2026) Kementerian Kesihatan  Malaysia) (2023)   1. ***Member,*** Jawatankuasa Pemandu Pengurusan   Pelupusan Ubat-ubatan di Malaysia,  Kementerian Kesihatan Malaysia (2023)   1. Health White Paper Engagement with   the Economic Planning Unit, Ministry of Health (MOH), Pharmaceutical Association of Malaysia (PhAMA),  Association of Malaysian Medical Industries (AMMI), Malaysian Organisation of Pharmaceutical Industries (MOPI) and Malaysian Association of Pharmaceutical Suppliers (MAPS) and Malaysia Medical Device  Association (MMDA). 2022   1. Real-World Evidence in Leveraging Therapeutic Outcomes. ***Co-chair.*** 2020. Supported by Novartis. 2. Real-World Evidence in Regulatory Decision-making. ***Speaker.*** Supported by Novartis Malaysia. September 2021 3. Virtual Symposium: Elements of Value based Decision-making in Health care. Supported by Novartis Malaysia. ***Programme Chair and Speaker.*** September 2021. 4. Novartis ***Advisory Board Member*** 2.0: CVD state,   challenges, unmet needs and potential  solutions for Malaysia. 2019   1. Novartis ***Advisory Board Member***: Breast cancer in Malaysia (2019) 2. ***Scientific Advisor,*** Clinical Research Committee,   Pharmaceutical Association of Malaysia  (PhAMA) (2023)   1. Market Access and Procurement Committee, Pharmaceutical Association of Malaysia (PhAMA). ***Scientific Advisor.*** 2023. 2. Workshop for the Ministry of Health on   Rare Disease: From Health Economics  Evaluation Perspective – ***Chair & Moderator***  (Supported by Boehringer-Ingelheim)   1. Asia-Pacific Economic Cooperation (APEC) Healthcare Financing Forum: Enhancing innovative healthcare financing, in the pursuit of sustainable healthcare. ***Moderator.*** September 2022. Supported by APEC. 2. Annual Monash-Pharmaceutical Association of Malaysia HTA Workshop for the Pharmaceutical Industry. ***Speaker.*** 2015-2021. Supported by PhAMA. 3. Health Economics for Healthcare Professionals. Supported by Novartis (Oncology). ***Chair.*** 21 May 2022 4. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Monash University Student Chapter***, Advisor,*** 2018-2021 5. 3rd - 6th Health Economics Forum 2022, November 2022, co-organised with Ministry of Health Malaysia and PhAMA. Supported by Johnson & Johnson, Zuellig Pharma, IQVIA, AstraZeneca, MSD, Novartis, Boehringer-Ingelheim, and Servier: ***Co-chair (2015 – 2022)*** 6. 7th Health Economics Forum 2024: ***Co-chair*** (2024) 7. ***Member,*** Pharmacy Academics Task Force (Malaysian Pharmaceutical Society) Member 2015 – 2017 8. ***Member***, Joint Human Ethics Committee of School of Pharmaceutical Sciences, USM-Hospital Lam Wah Ee on Clinical Studies (2007-2009) |
| **19** | **COMMUNITY SERVICE** | NA |